![Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2011.36.5742/asset/images/zlj9991016430002.jpeg)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Journal of Clinical Oncology
![Cancers | Free Full-Text | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer Cancers | Free Full-Text | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer](https://pub.mdpi-res.com/cancers/cancers-13-03738/article_deploy/html/images/cancers-13-03738-ag.png?1627272489)
Cancers | Free Full-Text | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
![First‐line Gemcitabine plus Nab‐paclitaxel Progression‐Free Survival... | Download Scientific Diagram First‐line Gemcitabine plus Nab‐paclitaxel Progression‐Free Survival... | Download Scientific Diagram](https://www.researchgate.net/publication/342073861/figure/fig2/AS:11431281179295658@1691170582039/First-line-Gemcitabine-plus-Nab-paclitaxel-Progression-Free-Survival-per-ECOG-performance.png)
First‐line Gemcitabine plus Nab‐paclitaxel Progression‐Free Survival... | Download Scientific Diagram
![Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer](https://pub.mdpi-res.com/life/life-12-00327/article_deploy/html/images/life-12-00327-ag.png?1645693413)
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
![Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology](https://mednexus.org/cms/10.1097/JP9.0000000000000038/asset/c28bb572-1302-4653-9250-7ce30dad7578/assets/graphic/2096-5664-03-01-005-f001.png)
Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer | Journal of Pancreatology
![Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram](https://www.researchgate.net/publication/324194801/figure/fig2/AS:961421936451628@1606232260744/Subgroup-analyses-for-progression-free-survival-with-nab-paclitaxel-plus-gemcitabine-AG.gif)
Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram
![Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-018-0784-z/MediaObjects/12325_2018_784_Fig1_HTML.png)
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States | Advances in Therapy
![Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study - ScienceDirect Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804920313046-gr1.jpg)
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study - ScienceDirect
![Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study](https://www.mdpi.com/cancers/cancers-13-02797/article_deploy/html/images/cancers-13-02797-g001.png)
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
![Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-5183-y/MediaObjects/12885_2018_5183_Fig1_HTML.png)
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
![PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9c7d29ebccc5e3fac1b7a68fa9515274ea592f76/8-Table2-1.png)
PDF] Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. | Semantic Scholar
![A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-023-11035-6/MediaObjects/12885_2023_11035_Fig1_HTML.png)
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text
![Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/43a6e2a8-6137-4582-897c-d270bdc65b12/gr2.jpg)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial - The Lancet Gastroenterology ... Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial - The Lancet Gastroenterology ...](https://www.thelancet.com/cms/attachment/673815a5-2166-4af5-95ec-4f25502316de/gr1.gif)
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial - The Lancet Gastroenterology ...
![Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer | British Journal of Cancer Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fbjc.2016.185/MediaObjects/41416_2016_Article_BFbjc2016185_Fig3_HTML.jpg)
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer | British Journal of Cancer
![The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-32591-8/MediaObjects/41467_2022_32591_Fig1_HTML.png)
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
![Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/e2916075-4a0f-4aac-8bbd-8817585876bd/gr1.gif)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan](https://journals.sagepub.com/cms/10.1177/17588359211035983/asset/images/large/10.1177_17588359211035983-fig1.jpeg)